Fibrinolytic and antithrombotic regimens in recently completed, ongoing and planned clinical trials in myocardial infarction.

Myocardial infarction carries significant short-term and long-term risks of morbidity and mortality. Traditional treatment for acute myocardial infarction has significantly improved the outcomes of patients suffering from this condition. Recent clinical trials have focused on the use of novel fibrinolytics, glycoprotein IIb/IIIa receptor antagonists, low-molecular-weight heparin, direct thrombin inhibitors and myocardial protection, in an attempt to improve the prognosis of these patients. This clinical trials report reviews the rationale and design of recently completed, ongoing and planned major Phase II and III clinical trials on fibrinolytic and antithrombotic regimens for the treatment of myocardial infarction.